167 related articles for article (PubMed ID: 15313894)
1. Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sézary syndrome identified by gene expression analysis.
van Doorn R; Dijkman R; Vermeer MH; Out-Luiting JJ; van der Raaij-Helmer EM; Willemze R; Tensen CP
Cancer Res; 2004 Aug; 64(16):5578-86. PubMed ID: 15313894
[TBL] [Abstract][Full Text] [Related]
2. EPHA4 is overexpressed but not functionally active in Sézary syndrome.
Hameetman L; van der Fits L; Zoutman WH; Out-Luiting JJ; Siegal G; de Esch IJ; Vermeer MH; Tensen CP
Oncotarget; 2015 Oct; 6(31):31868-76. PubMed ID: 26376612
[TBL] [Abstract][Full Text] [Related]
3. Epigenomic Analysis of Sézary Syndrome Defines Patterns of Aberrant DNA Methylation and Identifies Diagnostic Markers.
van Doorn R; Slieker RC; Boonk SE; Zoutman WH; Goeman JJ; Bagot M; Michel L; Tensen CP; Willemze R; Heijmans BT; Vermeer MH
J Invest Dermatol; 2016 Sep; 136(9):1876-1884. PubMed ID: 27113428
[TBL] [Abstract][Full Text] [Related]
4. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
[TBL] [Abstract][Full Text] [Related]
5. Novel and highly recurrent chromosomal alterations in Sézary syndrome.
Vermeer MH; van Doorn R; Dijkman R; Mao X; Whittaker S; van Voorst Vader PC; Gerritsen MJ; Geerts ML; Gellrich S; Söderberg O; Leuchowius KJ; Landegren U; Out-Luiting JJ; Knijnenburg J; Ijszenga M; Szuhai K; Willemze R; Tensen CP
Cancer Res; 2008 Apr; 68(8):2689-98. PubMed ID: 18413736
[TBL] [Abstract][Full Text] [Related]
6. Tumor suppressor TNFAIP3 (A20) is frequently deleted in Sézary syndrome.
Braun FC; Grabarczyk P; Möbs M; Braun FK; Eberle J; Beyer M; Sterry W; Busse F; Schröder J; Delin M; Przybylski GK; Schmidt CA
Leukemia; 2011 Sep; 25(9):1494-501. PubMed ID: 21625233
[TBL] [Abstract][Full Text] [Related]
7. CD164 identifies CD4
Benoit BM; Jariwala N; O'Connor G; Oetjen LK; Whelan TM; Werth A; Troxel AB; Sicard H; Zhu L; Miller C; Takeshita J; McVicar DW; Kim BS; Rook AH; Wysocka M
Arch Dermatol Res; 2017 Jan; 309(1):11-19. PubMed ID: 27766406
[TBL] [Abstract][Full Text] [Related]
8. Increased Twist expression in advanced stage of mycosis fungoides and Sézary syndrome.
Goswami M; Duvic M; Dougherty A; Ni X
J Cutan Pathol; 2012 May; 39(5):500-7. PubMed ID: 22515221
[TBL] [Abstract][Full Text] [Related]
9. Induction of T-cell responses against cutaneous T-cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA.
Ni X; Richmond HM; Liao XM; Decker WK; Shiue LH; Shpall EJ; Duvic M
J Invest Dermatol; 2008 Nov; 128(11):2631-2639. PubMed ID: 18480841
[TBL] [Abstract][Full Text] [Related]
10. Application of a multiprobe RNase protection assay and junctional sequences to define V beta gene diversity in Sezary syndrome.
Kono DH; Baccala R; Balderas RS; Kovac SJ; Heald PW; Edelson RL; Theofilopoulos AN
Am J Pathol; 1992 Apr; 140(4):823-30. PubMed ID: 1562047
[TBL] [Abstract][Full Text] [Related]
11. Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells.
Kennah E; Ringrose A; Zhou LL; Esmailzadeh S; Qian H; Su MW; Zhou Y; Jiang X
Blood; 2009 May; 113(19):4646-55. PubMed ID: 19211505
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
13. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome.
van Doorn R; van Kester MS; Dijkman R; Vermeer MH; Mulder AA; Szuhai K; Knijnenburg J; Boer JM; Willemze R; Tensen CP
Blood; 2009 Jan; 113(1):127-36. PubMed ID: 18832135
[TBL] [Abstract][Full Text] [Related]
14. The molecular pathogenesis of mycosis fungoides and Sézary syndrome.
Döbbeling U
G Ital Dermatol Venereol; 2008 Dec; 143(6):385-94. PubMed ID: 19169211
[TBL] [Abstract][Full Text] [Related]
15. SHP-1 expression in peripheral T cells from patients with Sezary syndrome and in the T cell line HUT-78: implications in JAK3-mediated signaling.
León F; Cespón C; Franco A; Lombardía M; Roldán E; Escribano L; Harto A; González-Porqué P; Roy G
Leukemia; 2002 Aug; 16(8):1470-7. PubMed ID: 12145687
[TBL] [Abstract][Full Text] [Related]
16. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
Zaki MH; Shane RB; Geng Y; Showe LC; Everetts SE; Presky DH; Wysocka M; Moore JS; Rook AH
J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
[TBL] [Abstract][Full Text] [Related]
17. TOX expression in different subtypes of cutaneous lymphoma.
Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
[TBL] [Abstract][Full Text] [Related]
18. Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome).
Cirée A; Michel L; Camilleri-Bröet S; Jean Louis F; Oster M; Flageul B; Senet P; Fossiez F; Fridman WH; Bachelez H; Tartour E
Int J Cancer; 2004 Oct; 112(1):113-20. PubMed ID: 15305382
[TBL] [Abstract][Full Text] [Related]
19. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
Yoo EK; Cassin M; Lessin SR; Rook AH
J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
[TBL] [Abstract][Full Text] [Related]
20. Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome.
Caprini E; Bresin A; Cristofoletti C; Helmer Citterich M; Tocco V; Scala E; Monopoli A; Benucci R; Narducci MG; Russo G
Cell Death Dis; 2018 Dec; 9(12):1178. PubMed ID: 30518749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
